Cargando…

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma

Malignant pleural mesothelioma is a rare but devastating cancer of the pleural lining with no effective treatment. The tumour is often diffusely spread throughout the chest cavity, making surgical resection difficult, while systemic chemotherapy offers limited benefit. Bone marrow-derived mesenchyma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sage, Elizabeth K, Kolluri, Krishna K, McNulty, Katrina, Lourenco, Sofia Da Silva, Kalber, Tammy L, Ordidge, Katherine L, Davies, Derek, Gary Lee, Y C, Giangreco, Adam, Janes, Sam M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078753/ https://www.ncbi.nlm.nih.gov/pubmed/24567297 http://dx.doi.org/10.1136/thoraxjnl-2013-204110

Ejemplares similares

Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience
por: Taylor, Bethany Hope, et al.
Publicado: (2019)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Understanding clinical decision-making in mesothelioma care: a mixed methods study
por: Henshall, Catherine, et al.
Publicado: (2022)

Cell migration leads to spatially distinct but clonally related airway cancer precursors
por: Pipinikas, Christodoulos P, et al.
Publicado: (2014)

Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy
por: Yuan, Zhengqiang, et al.
Publicado: (2016)

Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT
por: Patrick, P. Stephen, et al.
Publicado: (2020)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT)
por: Kummer, Sonja, et al.
Publicado: (2020)

Defining the information needs of lung cancer screening participants: a qualitative study
por: Ruparel, Mamta, et al.
Publicado: (2019)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Evaluation of cardiovascular risk in a lung cancer screening cohort
por: Ruparel, Mamta, et al.
Publicado: (2019)

Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial
por: Woznitza, Nick, et al.
Publicado: (2023)

TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy
por: Yuan, ZhengQiang, et al.
Publicado: (2017)

Prevalence and clinical characteristics of non-malignant CT detected incidental findings in the SUMMIT lung cancer screening cohort
por: Tisi, Sophie, et al.
Publicado: (2023)

Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
por: Woodford, Katrina, et al.
Publicado: (2022)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity
por: Vallath, Sabari, et al.
Publicado: (2016)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
por: Kolluri, Krishna Kalyan, et al.
Publicado: (2018)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models
por: Raghu, Vineet K, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma
por: Mack, Philip C, et al.
Publicado: (2022)

UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
por: Baldwin, D R, et al.
Publicado: (2011)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
por: Gray, Jhanelle, et al.
Publicado: (2021)

Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
por: Brain, Kate, et al.
Publicado: (2017)

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer
por: Sibille, A., et al.
Publicado: (2021)

Hospital-based multidisciplinary lung cancer care in Australia: a survey of the landscape in 2021
por: Brims, Fraser J H, et al.
Publicado: (2022)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
por: Brain, Kate, et al.
Publicado: (2016)

Management of Lung Cancer in the Patient with Interstitial Lung Disease
por: Frank, Angela J, et al.
Publicado: (2022)

Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set
por: Edbrooke, Lara, et al.
Publicado: (2023)

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
por: Clive, Amelia O, et al.
Publicado: (2014)

Cone beam CT-guided navigation bronchoscopy: a cost-effective alternative to CT-guided transthoracic biopsy for diagnosis of peripheral pulmonary nodules
por: Kops, Stephan E P, et al.
Publicado: (2022)

What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
por: O'Dowd, Emma L, et al.
Publicado: (2015)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS)
por: Abraham, Christopher, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hjuilvejdj6a6bhe48ueoto3he